




that	occupy	 the	human	digestive	 tract.	The	accumulation	of	 these	microorganism	species	
begins	 soon	 after	 birth,	 developing	 rapidly	 through	 early	 childhood.	 Various	 factors	
throughout	life	can	affect	the	ecology	and	function	of	the	microbiota,	potentially	resulting	
in	 dysbiosis,	 the	 alternation	 of	 microbiota	 such	 that	 an	 imbalance	 is	 created	 between	
beneficial	 and	 harmful	 bacteria	 throughout	 the	 gut9.	 Disruption	 of	 the	 gut	microbiota	 is	
associated	with	multiple	diseases	of	the	gastrointestinal	tract	(GIT),	such	as	irritable	bowel	
disease	(IBD)	and	inflammatory	bowel	syndrome	(IBS),	as	well	as	causation	of	Clostridium	







skin,	 nasal	 and	 oral	 cavity,	 urogenital	 tract,	 and	 GIT.	 In	 the	 gut,	 these	 communities	 are	








species	 become	 predominant	 throughout	 the	 distal	 ileum	 and	 colon;	 in	 the	 distal	 ileum	
Escherichia	coli	is	most	common,	whereas	in	the	colon	species	of	the	Bacteroides	genus	are	
more	 frequent10.	 Throughout	 the	 remainder	 of	 the	 life	 cycle,	 the	 gut	microbiota	 remains	
relatively	 stable.	 In	 general,	 a	 healthy	microbiota	 is	 characterized	 by	 high	 diversity	 and	
ability	 to	 resist	 change	 under	 physiological	 stress.	 Unhealthy	microbiota	 is	 the	 opposite,	
distinguished	by	lower	species	diversity,	 in	addition	to	fewer	beneficial	microbes	and	the	
presence	of	pathobionts9.	
Gut	microbiota	 are	 crucial	 for	many	 processes	within	 the	 human	 body,	 including	
intestinal	tract	development,	systemic	immunity,	colonic	homeostasis,	aiding	in	digestion,	
and	 the	 formation	 of	 certain	 nutrients9,10.	 Nutrients	 produced	 by	microbial	 action	 in	 the	
colon	include	vitamin	K,	vitamin	B12,	thiamin,	and	riboflavin.	While	these	nutrients	do	not	
significantly	contribute	to	the	micronutrient	needs	of	the	host,	they	are	used	by	intestinal	
mucosal	 cells10.	 In	 addition	 to	 nutrients,	 the	 gut	microbiota	 also	 aid	 in	 the	 formation	 of	
short	 chain	 fatty	 acids	 and	 certain	 gases.	 Butyrate,	 one	 of	 the	 short	 chain	 fatty	 acids	




understand	the	microbial	communities	 that	 inhabit	 the	human	body.	One	such	registry	 is	
the	Human	Microbiome	Project,	sponsored	by	the	US	National	 Institutes	of	Health,	which	
involves	categorizing	and	describing	the	microbial	communities	in	the	human	body.	More	





developing	 pill	 versions	 of	 FMT,	 using	 the	 information	 available	 through	 the	 Human	





Despite	 the	 stability	 of	 the	 gut	 microbiota	 throughout	 life,	 various	 factors	 can	
potentially	play	a	role	in	disrupting	the	complex	microorganism	community	established	in	
the	 gut.	 Factors	 that	 may	 impact	 the	 gut	 microbiota	 include	 stress,	 alcohol,	 exercise,	
unnecessary	use	of	antibiotics,	 excessive	hygiene,	and	dietary	choices4,9.	Dietary	antigens	
interact	with	both	the	intestinal	mucosa	and	directly	with	the	microbiota	as	well.	There	is	
evidence	 that	 diet	 has	 profound	 effects	 on	 the	 composition	 of	 the	 gut	microbiota4.	 	 For	
instance,	 dietary	 patterns	 including	 regular	 red	 meat	 consumption	 tend	 to	 favor	






of	 antibiotic	 treatments,	 and	 chlorinated	 versus	 non-chlorinated	 water6.	 Clearly,	 dietary	





makeup	 in	 such	 a	 way	 that	 can	 lead	 to	 decreased	 systemic	 immunity4,6.	 Originally	 only	
polysaccharides	were	included	as	dietary	fiber,	but	more	recent	definitions	have	expanded	
to	include	oligosaccharides	as	well,	based	on	their	physiological	effects16.	Dietary	fibers	are	
defined	 as	 indigestible	 carbohydrates	 and	 lignin	 that	 are	 intrinsic	 and	 intact	 in	 plants16.	
Oligosaccharides	 are	 the	 most	 well	 known	 prebiotics,	 and	 stimulate	 Bifidobacterium,	 a	
beneficial	 bacterial	 genus	 of	 the	 GIT.	 Other	 fiber	 sources	 have	 similar	 effects,	 including	
polydextrose,	wheat	dextrin,	psyllium,	banana,	whole	grain	wheat,	 and	whole	grain	 corn.	
All	prebiotics	are	fiber,	but	not	all	fiber	are	prebiotics16.	
Microbial	 imbalance	 is	associated	with	various	human	diseases	of	 the	GIT,	namely	
IBD,	 both	Crohn’s	disease	 and	ulcerative	 colitis	 (UC),	 and	 inflammatory	bowel	 syndrome	
(IBS).	Patients	with	IBD	have	overall	reduced	microbial	biodiversity.	More	specifically,	IBD	
patients	 have	 reduced	 anti-inflammatory	 associated	 Faecalibacterium	 prausnitzii,	
increased	sulfide	generating	Desulfovibrio	subspecies	and	Fusobacterium	varium	that	can	
invade	 epithelium,	 reduced	 Bacteriodetes,	 and	 enriched	 Actinobacteria	 and	
Proteobacteria9.	IBS	patients	have	altered	carbohydrate	and	protein	energy	metabolism	in	
the	 gut	 secondary	 to	 changes	 in	 the	 diversity	 of	 the	 gut	microbiota.	 Poor	 absorption	 of	
dietary	 carbohydrate	 induces	 prolonged	 intestinal	 hydrogen	 production.	 Fecal	 samples	
from	 patients	 with	 diarrhea	 dominated	 IBS	 show	 increased	 Lactobacillus,	 Veillonella,	
Prevotella,	and	Parasporo,	and	decreased	Bifidobacteria	and	Verrucomicrobium9.	
Aside	from	diseases	of	the	bowel,	dysbiosis	can	lead	to	C.	difficile	infection.	C	difficile	





infection	was	 estimated	 to	 cause	 almost	 half	 a	million	 infections	 in	 the	 United	 States	 in	




two	 or	more	 days,	 fever,	 loss	 of	 appetite,	 nausea,	 and	 abdominal	 pain	 and	 tenderness12.	
Treatment	 for	 recurrent	 C.	 difficile	 is	 limited.	 Current	 protocol	 is	 to	 discontinue	 other	
antibiotics	when	possible	and	start	another	antibiotic	such	as	metronidazole,	vancomycin,	
or	 fidaxomicin	 by	mouth	 for	 a	minimum	of	 10	 days.	 Return	 of	 infection	 occurs	 in	 about	
twenty	percent	of	patients;	the	first	return	of	C.	difficile	is	generally	treated	using	the	same	
antibiotic	used	 for	 the	 first	 occurrence,	whereas	 it	 is	 recommended	 to	manage	all	 future	




Many	 approaches	 exist	 to	 manage	 the	 gut	 microbiome,	 or	 aid	 in	 the	 reversal	 of	
dysbiosis	when	it	occurs.	There	are	three	main	categories	of	therapy	used	either	to	prevent	
or	 treat	 dysbiosis.	 The	 first	 two	 are	 existing	 therapies	 that	 have	 been	 used	 and	 studied	
much	 more	 extensively;	 the	 first	 being	 prebiotics,	 probiotics,	 and	 symbiotics,	 and	 the	
second	 being	 antibiotics.	 Prebiotics	 are	 defined	 as	 indigestible	 food	 compounds	 that	
selectively	stimulate	specific	beneficial	microbial	species	already	present	in	the	gut,	such	as	




lining	 the	 intestinal	 tract10.	 Probiotics	 are	 beneficial	 live	 microorganisms	 that	 suppress	
potentially	harmful	microbes	and	as	a	result,	contribute	to	a	healthy	GIT	environment6,10.	
Symbiotics	 are	 a	 combination	 of	 prebiotics	 and	 probiotics;	 they	 are	 prebiotic	 food	
ingredients	that	ferment	to	short	chain	fatty	acids	in	the	GIT10.	Antibiotics	have	also	been	
studied	 extensively	 as	 the	 primary	 pharmacological	 approach	 to	 eradicating	 pathogens.	







The	 third	 category	 of	 bacteriotherapy	 is	 a	 more	 novel	 approach	 that	 has	 gained	
popularity	more	recently,	secondary	to	its	efficiency	and	safety	especially	as	compared	to	
antibiotics.	 This	 therapy	 is	 termed	 fecal	 microbiota	 transplantation	 (FMT),	 but	 is	 also	
commonly	referred	to	as	fecal	transplant	or	stool	transplant.	Fecal	transplants	are	used	to	








nasoduodenal	 tube,	 colonoscopy,	 oral	 fecal	 capsules,	 or	 self-administered	 enemas8.	 Each	
route	 of	 administration	 has	 advantages	 and	 disadvantages,	 as	with	 all	 other	 procedures.	
Use	 of	 a	 nasogastric	 tube	 for	 fecal	 transplant	 is	 the	 least	 effective	method,	with	 success	
rates	ranging	from	seventy-three	to	eighty-three	percent.	However,	it	is	easier	to	perform	
and	poses	lower	risks	to	the	patient	than	the	other	mentioned	alternatives8.	When	given	via	
colonoscopy,	 the	 colonic	muscosa	may	 be	 examined	 directly	 and	 any	 abnormal	 findings	
documented,	 stool	 can	be	 infused	 throughout	 the	entire	 length	of	 the	colon,	and	patients	







reported	 as	 a	 treatment	 strategy	 used	 for	 the	 treatment	 of	 C.	 difficile1.	 FMT	 works	 by	
reintroducing	 healthy	 bacteria	 to	 a	 diseased	 bowel	 and	 reestablishing	 colonization.	 This	
colonization	provides	resistance	to	lessen	the	dominance	of	the	C.	difficile	organism	in	the	
gut.	The	best	candidates	for	FMT	have	had	three	or	more	recurrences	of	C.	difficile	and	have	
failed	 other	 more	 conventional	 therapies,	 such	 as	 an	 antibiotic	 course,	 and/or	 become	
severely	 ill	due	to	the	C.	difficile	 infection	whether	or	not	the	current	 infection	is	the	first	
occurrence.	The	American	College	of	Gastroenterology	now	recommends	fecal	transplants	
as	 treatment	after	 a	 third	 reoccurrence	of	C.	difficile8.	More	debatable	 is	 that	 any	patient	
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with	 a	 current	 C.	 difficile	 infection	 may	 be	 a	 candidate	 for	 this	 procedure1.	 As	 for	
contraindications,	at	present	there	currently	are	none1.	
Efficiency	 of	 FMT	 is	 profound.	 As	 of	 2012,	 there	 had	 been	 at	 least	 twenty	 seven	
published	case	 series	 that	address	 fecal	 transplants,	 including	both	small	 case	 series	and	
individual	case	reports;	on	average,	FMT	cure	rates	were	found	to	be	ninety	one	to	ninety	
three	 percent.	 One	 study	 by	 Kelly	 et	 al	 in	 2012	 reported	 the	 results	 of	 a	 retrospective,	




ninety	 percent3.	 An	 additional	 publication	 during	 2013	 reported	 similar	 results;	 this	
publication	 evaluated	 data	 of	 two	 systematic	 reviews	 consisting	 of	 317	 patients	 across	
twenty-seven	case	series	and	124	patients	across	seven	case	series,	respectively.	The	first	
systematic	 review	 highlighted	 a	 disease	 improvement	 or	 resolution	 rate	 of	 ninety-two	
percent,	while	the	second	found	eighty-three	percent5.	Based	on	these	three	publications,	
the	efficiency	of	FMT	in	treating	C.	difficile	is	greater	than	80%	in	all	studies.	
Donor	 selection	 is	 another	 key	 component	 of	 FMT.	 Generally,	 after	 the	 patient	 is	
educated	 on	 the	 donor	 selection	 criteria,	 the	 patient	 them	 self	 finds	 a	 donor.	 The	 donor	
tends	to	be	either	someone	the	patient	 is	 intimate	with	or	a	 first-degree	relative,	but	can	
also	 be	 a	 complete	 stranger.	 It	 is	 preferred	 that	 the	 donor	 be	 someone	 that	 patient	 is	
intimate	with,	but	other	donors	are	suitable8.	Criteria	for	donor	selection	is	not	extensive,	
but	 are	 important	 to	 be	 met	 by	 whoever	 the	 donor	 is.	 Donor	 stool	 must	 be	 free	 from	







they	 will	 be	 disqualified	 as	 a	 donor1.	 The	 potential	 donor	 must	 meet	 certain	
gastrointestinal	 criteria	as	well;	 they	will	 generally	be	excluded	 if	 they	 currently	have	or	
have	a	history	of	IBD,	IBS,	chronic	constipation,	or	chronic	diarrhea1.	Other	syndromes	that	
may	 disqualify	 an	 individual	 as	 a	 stool	 donor	 include	 metabolic	 syndrome,	 systemic	
autoimmunity,	 atopic	 disease,	 or	 chronic	 pain	 syndrome1.	 Lastly,	 they	 must	 not	 have	
received	antibiotics,	or	other	major	immunosuppressive	medications,	within	the	past	three	
months	 for	 any	 reason.	 At	 this	 point	 donated	 human	 stool	 is	 being	 used	 for	 FMT	
procedures,	hence	 the	 importance	of	donor	selection.	However,	 synthetic	 stool	 for	use	 in	
fecal	 transplants	 is	 being	 studied	 given	 the	 increasing	 popularity	 of	 this	 procedure.	
University	 of	 Guelph	 researchers	 created	 synthetic	 feces,	 named	 RePOOPulate,	 after	
examination	 of	 the	 bacterial	 composition	 of	 stool	 from	 healthy	 volunteers.	 Two	 patients	











donor	 feces	 via	 a	 nasogastric	 tube,	 a	 standard	 vancomycin	 regimen,	 or	 a	 standard	
vacomycin	 regimen	 followed	 by	 bowel	 irrigation.	 Bowel	 irrigation	 refers	 to	 the	 rapid	
administration	 of	 large	 volumes	 of	 osmotically	 balanced	 polyethylene	 glycol	 electrolyte	
solution	 to	 flush	 out	 the	 gastrointestinal	 tract	 in	 entirety.	 Participants	 included	 in	 this	
study	were	eighteen	years	or	older,	had	a	life	expectancy	of	greater	than	3	months,	and	had	
a	history	of	C.	difficile	 infection	relapse	after	one	or	more	completed	courses	of	antibiotic	









noted.	A	majority	of	 the	patients	 in	the	 infusion	group,	ninety-four	percent,	had	diarrhea,	
while	 thirty-one	 percent	 reported	 cramping,	 thirteen	 percent	 experienced	 belching,	 and	
three	 patients	 had	 constipation.	 However,	 all	 symptoms	 resolved	 within	 three	 hours	
following	the	procedure2.	Interestingly	and	unique	to	this	particular	study,	fecal	microbiota	
from	patients	in	the	infusion	group	were	collected	and	evaluated	both	before	and	again	two	
weeks	 following	 the	 infusion.	 As	 expected,	 initially	 prior	 to	 infusion,	 patients’	 microbial	








Another	 study	 completed	 in	 2012	 by	 Jorup-Ronstrom	 et	 al	 discovered	 similar	
results	regarding	the	effectiveness	of	FMT7.	In	this	study,	feces	samples	were	donated	from	




Ten	 patients	 failed	 to	 respond	 fully;	 of	 these	 ten	 patients,	 three	were	 cured	 following	 a	
second	infusion	given	via	enema	and	four	after	a	second	transplant	given	by	colonoscopy7.	
No	 adverse	 effects	 were	 discovered	 throughout	 the	 course	 of	 this	 study	 and	 it	 was	
concluded	 that	 in	 patients	 with	 recurrent	 C.	 difficile	 infection,	 FMT	 is	 an	 effective	
alternative	treatment	when	antibiotic	therapies	fail.	In	terms	of	pharmacological	treatment,	
it	was	mentioned	in	this	study	that	antibiotic	regimens	were	found	to	produce	good	results	









Patient	 RS	was	 a	 sixty-nine	 year	 old	 Caucasian	male	who	 lived	 at	 home	with	 his	
spouse	and	previously	ran	a	small	business,	but	had	since	retired.	The	patient	reported	he	
was	 normally	 very	 active,	 cycled	 regularly,	 rarely	 used	 alcohol,	 and	 did	 not	 smoke.	
Medicare	was	 his	 payer	 source.	 He	was	 five	 foot	 eleven	 inches	 and	weighed	 sixty-three	
kilograms	 at	 the	 time	 of	 admission.	 His	 body	 mass	 index,	 calculated	 using	 these	
measurements,	was	19.4;	 this	value	 is	 indicative	of	normal	weight	status.	However,	given	
that	he	was	over	the	age	of	sixty-five,	his	 ideal	body	mass	 index	 is	between	twenty	three	




the	 patient	 included	 chronic	 diarrhea,	 cardiac	 sarcoidosis,	 celiac	 disease,	 hypoatremia,	
hypocalcemia,	 and	 recurrent	 C.	 difficile.	 His	 past	 medical	 history	 additionally	 included	
ventricular	 tachycardia,	 placement	 of	 an	 implantable	 cardiac	 defibrillator,	 diverticulitis,	







(PCP)	 and	 had	 a	 CT	 that	 showed	 sigmoid	 colon	 inflammation,	 at	 which	 point	 he	 was	
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having	 up	 to	 fifteen	 bowel	 movements	 per	 day.	 More	 recent	 to	 admission,	 he	 reported	
avoiding	 food	 and	 having	 seven	 to	 eight	 bloody	 bowel	movements	 a	 day.	 Over	 the	 eight	
weeks	leading	up	to	admission,	patient	RS	reported	a	twenty-one	pound	weight	loss.	
Within	 one	 day	 of	 admission,	 nutrition	 was	 consulted	 in	 order	 to	 initiate	 total	
parenteral	 nutrition	 (TPN).	 Following	 the	 American	 Society	 of	 Parenteral	 and	 Enteral	




The	 patient	 also	 had	 an	 upper	 gastrointestinal	 and	 colonoscopy	 with	 biopsy	 completed	





poor	 intake	 by	 mouth	 for	 over	 a	 week,	 the	 patient	 met	 the	 criteria	 for	 moderate	






per	 medical	 team.	 The	 goals	 set	 for	 the	 patient	 included	 TPN	 to	 provide	 greater	 than	
eighty-five	 percent	 of	 goal	macronutrients	 and	 transition	 to	 intake	 by	mouth	 as	 soon	 as	
medically	feasible.	Only	one	recommendation	was	made	at	this	time,	which	was	to	initiate	
TPN	 based	 on	 labs	 once	 the	 central	 line	 was	 placed	 and	 confirmed.	 Additionally,	 the	
nutrition	 diagnosis	 of	 patient	 RS	 was	 established	 as	 altered	 gastrointestinal	 function	
related	to	physiologic	causes	as	evidenced	by	nothing	by	mouth	(NPO)	status	and	the	need	
for	TPN.	
The	 following	 day,	 the	medical	 team	was	working	with	 the	 patient	 regarding	 line	




Despite	 the	 patient’s	 need	 for	 TPN,	 he	 continued	 by	mouth	 intake	 throughout	 his	
stay	as	well,	when	otherwise	not	NPO	status	for	procedures.	During	the	first	few	days	of	his	
stay,	he	was	newly	diagnosed	as	Celiac	and	was	therefore	changed	to	a	gluten	free	diet.	A	











to	 start	 TPN	 that	 night	 at	 midnight.	 Also	 that	 morning,	 the	 patient	 underwent	 a	 stool	
transplant	 in	 gastrointestinal	 procedures	 in	 attempt	 to	 cure	 his	 recurrent	 C.	 difficile	
infection.	 His	 daughter	 served	 as	 the	 donor.	 Donor	 stool	was	 prepared	 using	 saline	 and	
approximately	500	mililiters	of	the	emulsified	donor	stool	was	instilled	from	the	cecum	to	
sigmoid	 colon	 using	 colonoscopy.	 The	 patient	 tolerated	 the	 procedure	 well	 and	 the	 C.	
difficile	 infection	was	alleviated.	Despite	alleviation	of	C	difficile,	 the	patient	 continued	 to	
have	multiple	gastrointestinal	problems,	namely	diarrhea,	 secondary	 to	 severe	UC.	While	









able	 to	 advance	 to	 macronutrient	 TPN	 goals	 within	 a	 few	 days.	 A	 metabolic	 cart	 was	
completed	within	 the	 first	week	 of	 beginning	 TPN,	 to	 better	 assess	 the	 patient’s	 resting	
metabolic	 rate.	The	 resting	energy	expenditure	 (REE)	determined	by	 this	procedure	was	
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1491,	 slightly	 less	 than	had	been	estimated.	 It	was	decided	 to	 feed	at	120	percent	of	 the	
REE,	1560	calories,	via	TPN,	as	the	patient	was	eating	by	mouth	as	well.	However,	after	two	
days	and	further	discussion	amongst	the	nutrition	support	team,	it	was	decided	that	given	
the	 patient’s	 continued	 diarrhea	 and	 likely	 minimal	 absorption,	 in	 addition	 to	 his	
malnourished	 state,	 that	 goal	 calories	 should	 be	 advanced	 further.	 At	 that	 time	 and	




with	 no	 reported	 nausea,	 vomiting,	 or	 abdominal	 pain.	 Patient	 RS	 additionally	 reported	
decreased	 frequency	 of	 bowel	movements,	 although	 all	 stools	 remained	 loose.	 However,	
within	the	next	week,	the	patient	suffered	multiple	episodes	of	loose	blood	loss	via	rectum.	
A	 flex	 sigmoidoscopy	 completed	 after	 these	 episodes	 showed	 worsening	 colitis	 and	
correlated	worsening	clinical	presentation.	The	medical	team	had	previously	mentioned	a	












Patient	 RS	 was	 a	 complicated	 case.	 He	 initially	 presented	 with	 chronic	 diarrhea,	
which	 was	 attributed	 primarily	 to	 a	 C.	 difficile	 infection	 upon	 his	 admission	 to	 UNC	
Hospitals.	This	infection	was	likely	caused	by	antibiotic	use	months	previously,	started	by	
his	 primary	 care	 provider	 to	 treat	 his	 recently	 diagnosed	 diverticulitis.	 The	 broad-
spectrum	antibiotic	 course	prescribed	 to	patient	RS	 is	 typical	 treatment	 for	diverticulitis	
and	acts	to	control	the	inflammation	in	the	colon.	Antibiotics	accomplish	this	by	reducing	
intestinal	bacteria	and	suppressing	the	intestine’s	immune	system.	In	most	patients	this	is	
effective	 treatment	 for	 acute	 diverticulitis;	 however,	 there	 are	 side	 effects	 to	 such	 an	
antibiotic	 course.	 One	 such	 side	 effect	 is	 the	 development	 of	 C.	 difficile	 infection.	 As	
discussed	previously,	C.	 difficile	 is	 found	 in	 the	 human	 gut,	 but	 is	 suppressed	 by	 various	
other	 microorganisms	 that	 cohabitate	 the	 intestinal	 tract.	 When	 the	 diversity	 of	 these	
microorganisms	 is	 reduced	 by	 broad-spectrum	 antibiotic	 use,	 the	 risk	 of	 developing	 C.	
difficile	 infection	is	significantly	increased	due	to	the	lack	of	suppressive	microorganisms.	
Therefore,	this	was	likely	the	primary	cause	of	his	presenting	infection.		
The	patient’s	 case	was	 further	 complicated	by	his	 underlying	 chronic	UC.	 Chronic	
diarrhea	 is	 a	 side	 effect	 of	 this	 condition	 as	 well.	 The	 congealed	 effects	 of	 the	 patient’s	
chronic	 UC,	 acute	 diverticulitis	 followed	 by	 treatment	 with	 an	 antibiotic	 course,	 and	




on	TPN	within	 the	 first	week	 (see	Appendix	A).	He	 then	underwent	a	 stool	 transplant	 in	
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order	 to	 treat	his	recurrent	C.	difficile	 infection.	Despite	other	complicating	 factors	 to	 the	
patient’s	course	of	stay,	this	procedure	was	successful	in	eliminating	his	infection	without	
further	use	of	antibiotics.	His	case	serves	to	strengthen	the	research	conducted,	evidence	
collected,	 and	 conclusions	 made	 regarding	 the	 efficiency	 of	 fecal	 transplants	 in	 treating	




has	 been	 research	 regarding	 FMT	 and	 treatment	 of	 UC	 as	 well,	 but	 the	 data	 is	 not	 as	




diarrheal	 symptoms	 continued.	 It	was	 at	 this	 point	 of	 the	patient’s	 stay	 that	 the	medical	
team	 began	 discussing	 the	 potential	 need	 for	 surgery.	 The	 patient	 resisted	 the	 idea	 of	
surgery,	preferring	to	try	steroidal	routes	of	treatment	instead.	When	this	failed	to	alleviate	






patient’s	 hospital	 stay,	 given	 that	 the	 treatment	 of	 his	 diverticulitis	 with	 an	 antibiotic	
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course,	 that	 ultimately	 lead	 to	 a	 C.	 difficile	 infection,	 was	 done	 prior	 to	 admission.	 One	
option	 would	 have	 been	 pursuing	 surgery	 earlier	 on	 in	 the	 course	 of	 stay	 to	 treat	 his	
underlying	 UC.	 However,	 it	 is	 understandable	 to	 pursue	 other	 treatment	 options	 before	
electing	 to	 perform	 surgery,	 especially	 for	 a	 condition	 that	 typically	 can	 be	managed	 by	
other	 means.	 While	 this	 case	 did	 highlight	 the	 efficiency	 of	 FMT	 for	 the	 treatment	 of	
recurrent	C.	difficile,	it	is	unfortunate	that	patient	RS	continued	to	have	complicating	factors	
that	 ultimately	 lead	 to	 necessary	 surgery.	 It	 may	 seem	 as	 if	 FMT	 was	 a	 meaningless	
undertaking	given	the	ultimate	outcome,	but	at	the	time	that	procedure	was	performed	it	
was	not	thought	that	the	patient	would	require	surgery.	
More	 information	would	 have	 been	 useful	 and	 interesting	 to	 know	 regarding	 this	
particular	case	study.	It	would	have	been	interesting	to	more	fully	understand	the	patient’s	
risk	 factors	 that	 lead	 to	his	C.	difficile	 infection,	such	as	his	dietary	pattern	outside	of	 the	
hospital,	stress	level,	exercise	frequency	and	intensity,	and	whether	he	was	born	vaginally	













In	 conclusion,	 FMT	 is	 an	 effective	 therapy	 in	 the	 treatment	of	C.	 difficile	 infection,	
despite	the	novelty	of	the	procedure.	There	are	minimal	adverse	effects	associated	with	the	
procedure	 and	 no	 current	 contraindications.	 Additionally,	 donor	 selection	 is	 a	 relatively	
simple	and	speedy	process,	and	the	results	of	the	procedure	are	promising.		
Patient	RS	 served	as	 an	example	 to	 further	enhance	 these	 conclusions.	His	 course	
was	complicated	by	a	variety	of	other	factors,	including	UC	and	a	recent	diagnosis	of	celiac	
disease,	but	FMT	was	successful	in	eliminating	his	C.	difficile	infection.		
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Na  128 135 141 140 139 133 133 133 138 136 136  130 130 127 138 136 137 136 134 134  
K  3.9 3.6 3.8 4.0 4.6 4.4 3.8 4.1 3.7 4.0 4.7  3.8 4.3 3.6 3.7 3.4 3.6 3.4 4.2 4.2  
Cl  97 99 104 106 106 100 101 105 107 108 102  104 103 99 106 105 106 103 102 105  
CO2  24 30 30 27 27 29 26 22 27 24 36  23 21 21 26 30 28 31 29 26  
BUN  3 10 12 14 15 15 15 17 20 17 16  12 8 10 14 19 17 15 16 13  




















0.56 0.51 0.60 0.51 0.58  
Glucose  102 205 149 141 134 143 128 101 127 143 114  69 406 98 143 120 135 88 92 127  
Ca  7.4 7.2 7.5 7.5 7.5 7.1 7.1 7.1 6.7 6.8 6.9  6.5 6.0 6.8 6.8 6.6 6.6 6.5 6.9 6.7  
Mg  1.7 2.1 2.1 1.8 1.7 1.6 1.9 2.0 2.0 2.1 1.8  1.9 1.6 1.6 1.8 1.6 2.0 1.6 1.8 1.8  
Phos  2.3 3.2 1.8 3.1 3.2 2.8 3.4 3.3  2.6 4.3  1.8 4.5 2.1 3.2 2.6 2.3 3.5 3.2 3.2  
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Reason for Consult:  
Assess and assist with TPN management 
 
Physical Examination: 
Height:  180.3 cm (5' 11")  BMI:  19.4  
Admit Weight:   63.1 kg   Ideal Body Weight  78.74 kg  
Current Weight:  63.05 kg (139 lb)  Percentage Ideal 
Body Weight  
 80%  
Dosing Weight:  63 kg   Adjusted Body 
Weight  
 N/A  
 
Weight history: 
Wt Readings from Last 3 Encounters:  
08/26/15  63.05 kg (139 lb)  
08/25/15  63.2 kg (139 lb 5.3 oz)  
 
Labs: 
BMP - Results in Past 2 Days 
Result Component  Current Result  
BUN/FP  5 (L) (8/26/2015)  
Chloride  99 (8/26/2015)  
CO2  23 (8/26/2015)  
Creatinine Whole 
Blood, POC  
0.92 (8/26/2015)  
EST.GFR (MDRD)  Not in Time 
Range  
Glucose  68 (8/26/2015)  
Potassium/FP  4.4 (8/26/2015)  




ASPEN Guidelines for Start of TPN: 
Evidence of protein-calorie malnutrition upon admission  
Anticipated duration of PN of at least 5-7 days  





PICC ordered, not yet placed 
Double lumen ordered-not yet placed 





69 yo male with persistent diarrhea x 8 weeks following multiple antibiotic courses and 
treatment for cdiff now with bloody stools, poor PO and continued diarrhea x 5/day or more 
within 30 min of eating food. S/p UGI and Colonoscopy today with inflammation diverticulitis IBD 
vs cdiff being worked up as well as Bx from samples taken during procedures today.  
 
Current nutrition therapy order: 
Nutrition Orders  
  




Pt currently unable to meet needs via clear liquids and has not met nutritional needs for months. 
Has lost weight over the past few months from ~75kg to 63.1 kg which is 15% of his total body 
weight, which is significant.  
 
ASPEN/Malnutrition Screening: 
 Pt meets criteria for moderate malnutrition d/t weight loss and poor po intake for over a week. 
 
Estimated Macro-Nutrient Needs: (dosing weight = 63) 
Estimated Energy Needs: 
 1890-2205 kcals/dau (30-35/kg) 
Estimated Protein Needs: 
 76-113g protein/day (1.2-1.8g/kg) 
Estimated Fluid Needs: 
 Per team, ~1mL/kcal 
Nutrition Goals: 
Provide > 85% of goal macronutrients via TPN 
Transition to po as soon as medically feasible 
 
Action/Recommendations:   
Will initiate TPN based on labs once line is placed and confirmed.   
 
Recommended TPN Formula:  
Recent TPN Orders (Show up to 1 orders ; newest on the right.)  
 None  
 
 
Nutrition Diagnosis:  
Altered GI function as related to physiologic causes-being worked up as evidenced by NPO 
status and need for TPN.  
 
Risk Protocols: 










BMP -  
Results in Past 2 Days 
Result Component  Current Result  
BUN/FP  3 (L) (8/31/2015)  
Chloride  97 (L) (8/31/2015)  
CO2  24 (8/31/2015)  
Creatinine Whole 
Blood, POC  
0.65 (L) 
(8/31/2015)  
EST.GFR (MDRD)  Not in Time 
Range  
Glucose  102 (8/31/2015)  
Potassium/FP  3.9 (8/31/2015)  
Sodium Serum  128 (L) 
(8/31/2015)  
 
Lab Results  
Component  Value  Date  
 CALCIUM  7.4*  08/31/2015  




Lab  Units  08/31/15 0354  




8/31: Dual lumen powerline placed this AM via VIR; TPN to start at midnight. No IVF currently 
running; current order for IVF has expired. Pt now s/p stool transplant in GI procedures this 
morning.  
8/27: Pt has not yet started on TPN. Consulted again, d/w team this morning regarding line, 
plan, blood cultures pending, and fevers over night. Awaiting placement of powerline for TPN 




69 yo male with persistent diarrhea x 8 weeks following multiple antibiotic courses and 
treatment for cdiff now with bloody stools, poor PO and continued diarrhea x 5/day or more 
within 30 min of eating food. S/p UGI and Colonoscopy today with inflammation diverticulitis IBD 
vs cdiff being worked up as well as Bx from samples taken during procedures today.  
 
Current nutrition therapy order: 
Nutrition Orders  
  
 Adult 3-in-1 TPN at 60 mL/hr starting at 09/01 0000  







Provide > 85% of goal macronutrients via TPN 
Transition to po as soon as medically feasible 
 
Action/Recommendations:   
Initiate TPN  
Monitor for refeeding syndrome-replete electrolytes as indicated 
Will order MET cart 
 
Recommended TPN Formula:  
Recent TPN Orders (Show up to 1 orders ; newest on the right.)  
 Start date and time  09/01/2015 0000   
  Adult 3-in-1 TPN 
[1185365696]  
 
 Order Status  Active   
 
 Macro Ingredients  
 amino acid (CLINISOL) 15%  90 g   
 dextrose  200 g   
 
 Electrolytes  
 sodium acetate  75 mEq   
 sodium chloride  110 mEq   
 sodium phosphate  15 mmol   
 potassium phosphate  15 mmol   
 
 Additives  
 mvi, adult no.4 with vit K 3,300 unit- 150 mcg/10 
mL  
10 mL   
 trace elements-5 (CONCENTRATED) Cr-Cu-Mn-
Se-Zn  
1 mL   
 
 Medications  
 thiamine  200 mg   
 
 QS Base  
 sterile water  166.29 mL   
 
 Lipids  
 fat emulsion 20 %  60 g   
 
 Calorie Contribution  
 Proteins  360 kcal   
 Dextrose  680 kcal   
 Lipids  600 kcal   
 Total  1,640 kcal   
 
 Electrolyte Ion Calculated Amount  
 Sodium  205 mEq   
 Potassium  22 mEq   
 Calcium  --   
		 		 						
	 30	
 Magnesium  --   
 Aluminum  --   
 Phosphate  30 mmol   
 Chloride  110 mEq   
 Acetate  75 mEq   
 
 Other  
 Total Protein  90 g   
 Total Protein/kg  1.47 g/kg   
 Glucose Infusion Rate  2.27 mg/kg/min   
 Osmolarity  1,662.64   
 Volume  1,440 mL   
 Rate  60 mL/hr   
 Dosing Weight  61.2 kg   
 Infusion Site  Central   
 
 Admin Instructions  
  --   
 
 
Nutrition Diagnosis:  









Reason for Follow-Up: Sign off from Adult TPN Service  
 
Nutrition Progress: 
Patient on TPN from 9/1 to 9/10.  
 
9/11/15: Pt transferred to MICU this AM secondary to bright red blood stool, lightheadedness, 
and hypotension. Per MD, will continue as planned with gluten free diet and d/c of TPN; pt did 
receive TPN until midnight last night and has been NPO today for scheduled sigmoidoscopy.  
 
Current nutrition therapy order: NPO currently for procedure; plan to resume pt on gluten free 
PO diet s/p procedure. 
 
Current Diet order:  
Nutrition Orders  
  










Recommend continue current nutrition therapy 
Recommend provide nutritional supplements per pt preference, when diet advanced from NPO 
Sign off to service RD to monitor at high nutrition risk  
 
Risk Protocols: 





Reason for Consult:  
Assess and assist with TPN management 
 
Physical Examination: 
Height:  180.3 cm (5' 11")  BMI:  19.5  
Admit Weight:   63.1 kg  Ideal Body Weight  78.74 kg  
Current Weight:  63.504 kg (140 lb)  Percentage Ideal 
Body Weight  
 80%  
Dosing Weight:  63 kg  Adjusted Body 
Weight  
 n/a  
 
Weight history: 
Wt Readings from Last 3 Encounters:  
09/14/15  63.504 kg (140 lb)  
08/25/15  63.2 kg (139 lb 5.3 oz)  
 
Labs: 
BMP -  
Results in Past 2 Days 
Result Component  Current Result  
BUN/FP  12 (9/15/2015)  
Chloride  104 (9/15/2015)  
CO2  23 (9/15/2015)  
Creatinine Whole 
Blood, POC  
0.56 (L) 
(9/15/2015)  
EST.GFR (MDRD)  Not in Time 
Range  
Glucose  69 (9/15/2015)  
Potassium/FP  3.8 (9/15/2015)  
Sodium Serum  130 (L) 
(9/15/2015)  
 
Lab Results  
Component  Value  Date  
 CALCIUM  6.5*  09/15/2015  






Lab  Units  09/15/15 1137  
MAGNESIUM  mg/dL  1.9  
 
ASPEN Guidelines for Start of TPN: 
Evidence of protein-calorie malnutrition upon admission  
Anticipated duration of PN of at least 5-7 days  
Documented inability to utilize the GI tract 
 
Parenteral Access: 
Replacement Date: 9/15 
Placed by: VIR 








9/15/15: Pt transferred from MICU to MDU service overnight; upon visit pt having rapid 
response and returning to MICU. Per MD note, sigmoidoscopy findings from procedure 9/11 
indicate worsening of his colitis with severe edema and friability; GI recommend colectomy over 
remicade given severity of colitis and anticipated poor response to medication. Pt currently 
seeking second opinions from GI contacts at Brigham and Women's. Pt associates severe 
malnutrition to poor eating opportunities with procedures and had been declining replacement of 
power line for TPN yesterday. However, Op note this AM indicate pt is undergoing tunneled 
central venous dual lumen powerline exchange to restart TPN.  
 
9/11/15: Pt transferred to MICU this AM secondary to bright red blood stool, lightheadedness, 
and hypotension. Per MD, will continue as planned with gluten free diet and d/c of TPN; pt did 
receive TPN until midnight last night and has been NPO today for scheduled sigmoidoscopy. 
 
Pt on TPN 9/1 to 9/10; discontinued secondary to adequate gluten free PO intake. 
 
Nutrition History:  
69 yo male with persistent diarrhea x 8 weeks following multiple antibiotic courses and 
treatment for cdiff now with bloody stools, poor PO and continued diarrhea x 5/day or more 
within 30 min of eating food. S/p UGI and Colonoscopy today with inflammation diverticulitis IBD 
vs cdiff being worked up as well as Bx from samples taken during procedures today. 
 
Current nutrition therapy order: 
Nutrition Orders  
  
 Adult 3-in-1 TPN at 60 mL/hr starting at 09/16 0000  





Estimated Macro-Nutrient Needs: (dosing weight = 63 kg) 
Estimated Energy Needs: 1890 - 2205 kcal (25-30 kcal/kg) 
Estimated Protein Needs: 76 - 113 gm (1.2-1.8 gm/kg) 
Estimated Fluid Needs: per MD 
 
MET cart completed 9/1: RQ 0.79, MEE 1491 x 120% = 1789 kcal 
  
Nutrition Goals: 
Provide > 85% of goal macronutrients via TPN 
Transition to po as soon as medically feasible 
 
Action/Recommendations:   
Replete potassium 
Replete phosphorus   
 
Recommended TPN Formula:  
Recent TPN Orders (Show up to 1 orders ; newest on the right.)  
 Start date and time  09/16/2015 0000   
  Adult 3-in-1 TPN 
[1187687415]  
 
 Order Status  Active   
 
 Macro Ingredients  
 amino acid (CLINISOL) 15%  100 g   
 dextrose  250 g   
 
 Electrolytes  
 sodium acetate  100 mEq   
 sodium chloride  60 mEq   
 sodium phosphate  30 mmol   
 potassium phosphate  21 mmol   
 
 Additives  
 mvi, adult no.4 with vit K 3,300 unit- 150 mcg/10 
mL  
10 mL   
 trace elements-5 (CONCENTRATED) Cr-Cu-Mn-
Se-Zn  
1 mL   
 
 Medications  
 thiamine  200 mg   
 
 QS Base  
 sterile water  46.19 mL   
 
 Lipids  
 fat emulsion 20 %  55 g   
 
 Calorie Contribution  
 Proteins  400 kcal   
 Dextrose  850 kcal   
 Lipids  550 kcal   
		 		 						
	 34	
 Total  1,800 kcal   
 
 Electrolyte Ion Calculated Amount  
 Sodium  200 mEq   
 Potassium  30.8 mEq   
 Calcium  --   
 Magnesium  --   
 Aluminum  --   
 Phosphate  51 mmol   
 Chloride  60 mEq   
 Acetate  100 mEq   
 
 Other  
 Total Protein  100 g   
 Total Protein/kg  1.57 g/kg   
 Glucose Infusion Rate  2.73 mg/kg/min   
 Osmolarity  1,908.65   
 Volume  1,440 mL   
 Rate  60 mL/hr   
 Dosing Weight  63.5 kg   
 Infusion Site  Central   
 
 Admin Instructions  




Nutrition Diagnosis:  
Altered GI function as related to physciological causes as evidenced by NPO status and need 
for TPN.  
 
Risk Protocols: 





Reason for Follow-Up: Sign off from Adult TPN Service  
 
Nutrition Progress: 
Patient on TPN from 9/16 to 9/23.  
 
9/23: Per MD progress note, 2/2 increasing leukocytosis, d/c central line and therefore TPN to 
r/o infection. Pt eating well per pt and RN; calorie count not indicative of meeting estimated 
needs, but PO intake is improving. Ostomy output 500 mL yesterday and 100 mL today. 
 
Current nutrition therapy order: Regular diet. 
 
Current Diet order:  








Current Medical Nutrition Therapy is appropriate although not meeting nutrient needs at this 
time. PO intake is improving; likely not meeting needs at this time. 
 
Dietitian Action/Recommendations: 
Recommend continue current nutrition therapy  
Recommend nutritional supplements per pt preference. 
Sign off to service RD to monitor at high nutrition risk  
 
Risk Protocols: 
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